+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Neuropathic Pain Drug Market by Type (Phantom Limb Pain, Post Herpetic Neuralgia, Post-traumatic Neuropathy), Treatment (Antidepressant Drugs Type, Multimodal Therapy, NSAIDs Type), Indication, Distribution, End User - Forecast 2024-2030

  • PDF Icon

    Report

  • 196 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 4968619
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Neuropathic Pain Drug Market size was estimated at USD 11.85 billion in 2023, USD 12.90 billion in 2024, and is expected to grow at a CAGR of 9.93% to reach USD 23.01 billion by 2030.The neuropathic pain drug includes pharmaceutical products designed to alleviate or manage pain caused by damaged nerves. This neuropathic pain drug comprises various medications such as antidepressants, anticonvulsants, local anesthetics, cannabinoids, and opioids and extends to prescription and over-the-counter drugs available through hospitals, pharmacies, clinics, and online platforms worldwide. The rising prevalence of diseases associated with neuropathic pain, such as diabetes mellitus and an aging population more susceptible to chronic pain conditions, are key factors driving the need for neuropathic pain drugs. Additionally, increased awareness of effective treatment options among healthcare professionals and patients has led to better diagnosis rates and higher demand for these medications. Advancements in pharmacological research have improved the understanding of neuropathic pain mechanisms and identified novel therapeutic targets. This progress has resulted in a strong pipeline of potential new therapies that could further bolster market growth. However, the neuropathic pain drug market also faces challenges, such as the lack of universally effective treatments due to significant variations among patients' experiences with neuropathic pain. Stringent regulatory requirements for drug approval add more time and cost to research and development processes. Investing in research & development efforts focused on novel therapeutic targets or more efficient drug delivery systems. Next-generation therapies such as gene therapy or personalized medicine approaches are promising in providing tailored treatments catering to individual patient profiles.

Regional Insights

In America, the rising geriatric population coupled with a high incidence of diabetes-induced peripheral neuropathy is expected to propel growth in this market. The United States showcases a considerable aging population and people suffering from neurological disorders, further creating demand for effective drugs. In APAC, emerging economies such as China, India, and Japan are experiencing rapid increases in healthcare expenditure and heightened awareness about neuropathic pain management. The APAC region also has a significant prevalence of diabetic patients globally, creating the need for effective drugs and therapeutics. EMEA presents a diverse landscape regarding healthcare infrastructure and disease prevalence; however, it still exhibits substantial scope for market expansion due to its well-established healthcare system in the European region, increased R&D investments from major pharmaceutical companies, and favorable reimbursement policies.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Neuropathic Pain Drug Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Neuropathic Pain Drug Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Neuropathic Pain Drug Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., Aptinyx Inc., Assertio Holdings, Inc., Astellas Pharma Inc., AstraZeneca PLC, Axsome Therapeutics, Inc., Bausch Health Companies Inc., Baxter International Inc., Biogen Inc., Bristol-Myers Squibb Company, CARA THERAPEUTICS, INC., Daiichi Sankyo Company, Limited, Eli Lilly and Company, GlaxoSmithKline PLC, Grünenthal Group, Johnson & Johnson Services Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Scilex Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Trevena Inc., and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Neuropathic Pain Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Phantom Limb Pain
    • Post Herpetic Neuralgia
    • Post-traumatic Neuropathy
    • Trigeminal Neuralgia
  • Treatment
    • Antidepressant Drugs Type
      • Serotonin Noradrenaline
      • Tricyclic Antidepressants
    • Multimodal Therapy
    • NSAIDs Type
      • Ibuprofen
      • Naproxen
  • Indication
    • Diabetic Neuropathy
    • Spinal Stenosis
  • Distribution
    • Online Pharmacies
    • Retail Pharmacies & Drug Stores
  • End User
    • Clinics
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Neuropathic Pain Drug Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Neuropathic Pain Drug Market?
  3. What are the technology trends and regulatory frameworks in the Neuropathic Pain Drug Market?
  4. What is the market share of the leading vendors in the Neuropathic Pain Drug Market?
  5. Which modes and strategic moves are suitable for entering the Neuropathic Pain Drug Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Neuropathic Pain Drug Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of neurological disorders and diabetic neuropathy worldwide
5.1.1.2. Significant preference for personalized medicines for neuropathic treatment
5.1.1.3. Increase in the geriatric population raises the demand for neuropathic pain management
5.1.2. Restraints
5.1.2.1. Product recall and high cost of new drug development
5.1.3. Opportunities
5.1.3.1. Ongoing clinical trial for neuropathic pain treatment
5.1.3.2. Rising number of specialty neuropathy and pain centers and efforts to boost distribution
5.1.4. Challenges
5.1.4.1. Side effects associated with neuropathic pain drug
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Neuropathic Pain Drug Market, by Type
6.1. Introduction
6.2. Phantom Limb Pain
6.3. Post Herpetic Neuralgia
6.4. Post-traumatic Neuropathy
6.5. Trigeminal Neuralgia
7. Neuropathic Pain Drug Market, by Treatment
7.1. Introduction
7.2. Antidepressant Drugs Type
7.3.1. Serotonin Noradrenaline
7.3.2. Tricyclic Antidepressants
7.3. Multimodal Therapy
7.4. NSAIDs Type
7.5.1. Ibuprofen
7.5.2. Naproxen
8. Neuropathic Pain Drug Market, by Indication
8.1. Introduction
8.2. Diabetic Neuropathy
8.3. Spinal Stenosis
9. Neuropathic Pain Drug Market, by Distribution
9.1. Introduction
9.2. Online Pharmacies
9.3. Retail Pharmacies & Drug Stores
10. Neuropathic Pain Drug Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Hospitals
11. Americas Neuropathic Pain Drug Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Neuropathic Pain Drug Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Neuropathic Pain Drug Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
14.3.1. Agreement, Collaboration, & Partnership
14.3.1.1. Eli Lilly strikes USD 630 million deal with Confo Therapeutics for non-opioid neuropathic pain drug
14.3.2. New Product Launch & Enhancement
14.3.2.1. Launch of AFD-NP Product For Neuropathic Pain Management
14.3.3. Award, Recognition, & Expansion
14.3.3.1. Akelos Receives NIH Grant To Continue Research On Nonopioid Alternative For Neuropathic Pain
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. Abbott Laboratories
15.1.2. AbbVie Inc.
15.1.3. Amgen Inc.
15.1.4. Aptinyx Inc.
15.1.5. Assertio Holdings, Inc.
15.1.6. Astellas Pharma Inc.
15.1.7. AstraZeneca PLC
15.1.8. Axsome Therapeutics, Inc.
15.1.9. Bausch Health Companies Inc.
15.1.10. Baxter International Inc.
15.1.11. Biogen Inc.
15.1.12. Bristol-Myers Squibb Company
15.1.13. CARA THERAPEUTICS, INC.
15.1.14. Daiichi Sankyo Company, Limited
15.1.15. Eli Lilly and Company
15.1.16. GlaxoSmithKline PLC
15.1.17. Grünenthal Group
15.1.18. Johnson & Johnson Services Inc.
15.1.19. Merck & Co., Inc.
15.1.20. Novartis AG
15.1.21. Pfizer Inc.
15.1.22. Regeneron Pharmaceuticals Inc.
15.1.23. Scilex Pharmaceuticals
15.1.24. Teva Pharmaceutical Industries Ltd.
15.1.25. Trevena Inc.
15.1.26. Vertex Pharmaceuticals Incorporated
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
List of Figures
FIGURE 1. NEUROPATHIC PAIN DRUG MARKET RESEARCH PROCESS
FIGURE 2. NEUROPATHIC PAIN DRUG MARKET SIZE, 2022 VS 2030
FIGURE 3. NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. NEUROPATHIC PAIN DRUG MARKET DYNAMICS
FIGURE 7. NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
FIGURE 8. NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2022 VS 2030 (%)
FIGURE 10. NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
FIGURE 12. NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2022 VS 2030 (%)
FIGURE 14. NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2022 VS 2030 (%)
FIGURE 16. NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 18. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 20. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 25. NEUROPATHIC PAIN DRUG MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 26. NEUROPATHIC PAIN DRUG MARKET SHARE, BY KEY PLAYER, 2022
List of Tables
TABLE 1. NEUROPATHIC PAIN DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 6. NEUROPATHIC PAIN DRUG MARKET SIZE, BY PHANTOM LIMB PAIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST HERPETIC NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST-TRAUMATIC NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 11. NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 13. NEUROPATHIC PAIN DRUG MARKET SIZE, BY SEROTONIN NORADRENALINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. NEUROPATHIC PAIN DRUG MARKET SIZE, BY MULTIMODAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 18. NEUROPATHIC PAIN DRUG MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. NEUROPATHIC PAIN DRUG MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 21. NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. NEUROPATHIC PAIN DRUG MARKET SIZE, BY SPINAL STENOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 24. NEUROPATHIC PAIN DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. NEUROPATHIC PAIN DRUG MARKET SIZE, BY RETAIL PHARMACIES & DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 27. NEUROPATHIC PAIN DRUG MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. NEUROPATHIC PAIN DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 52. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 53. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 54. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 55. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 56. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 57. CANADA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 59. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 60. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 61. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 62. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 63. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 64. MEXICO NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 73. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 74. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 78. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 79. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 81. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 82. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 83. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 84. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 85. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 86. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 87. AUSTRALIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 89. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 90. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 91. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 92. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 93. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 94. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 96. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 97. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 98. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 99. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 100. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 101. INDIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 103. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 104. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 105. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 106. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 107. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 108. INDONESIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 110. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 111. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 112. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 113. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 114. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 115. JAPAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 116. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 117. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 118. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 119. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 120. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 121. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 122. MALAYSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 124. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 125. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 126. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 127. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 128. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 129. PHILIPPINES NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 131. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 132. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 133. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 134. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 135. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 136. SINGAPORE NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 138. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 139. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 140. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 141. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 142. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 143. SOUTH KOREA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 145. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 146. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 147. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 148. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 149. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 150. TAIWAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 152. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 153. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 154. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 155. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 156. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 157. THAILAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 159. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 160. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 161. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 162. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 163. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 164. VIETNAM NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 173. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 174. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 175. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 176. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 177. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 178. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 179. DENMARK NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 181. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 182. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 183. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 184. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 185. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 186. EGYPT NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 188. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 189. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 190. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 191. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 192. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 193. FINLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 195. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 196. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 197. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 198. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 199. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 200. FRANCE NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 202. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 203. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 204. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 205. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 206. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 207. GERMANY NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 209. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 210. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 211. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 212. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 213. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 214. ISRAEL NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 216. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 217. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 218. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 219. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 220. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 221. ITALY NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 228. NETHERLANDS NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 230. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 231. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 232. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 233. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 237. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 238. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 239. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 240. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 241. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 242. NORWAY NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 244. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 245. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 246. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 247. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 248. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 249. POLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 251. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 252. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 253. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 254. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 255. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 256. QATAR NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 257. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 258. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 259. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 260. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 261. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 262. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 263. RUSSIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 266. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 268. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 270. SAUDI ARABIA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 271. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 272. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 273. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 274. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 276. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 279. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 280. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 281. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 282. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 283. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 284. SPAIN NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 285. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 286. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 287. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 288. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 289. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 290. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 291. SWEDEN NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 293. SWITZERLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 294. SWITZERLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 295. SWITZERLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 296. SWITZERLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 297. SWITZERLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 298. SWITZERLAND NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 299. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 300. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 301. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 302. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 303. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 304. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 305. TURKEY NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 306. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 307. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 308. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 309. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 310. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 311. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 312. UNITED ARAB EMIRATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 313. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 314. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 315. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
TABLE 316. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
TABLE 317. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 318. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 319. UNITED KINGDOM NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 320. NEUROPATHIC PAIN DRUG MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 321. NEUROPATHIC PAIN DRUG MARKET SHARE, BY KEY PLAYER, 2022
TABLE 322. NEUROPATHIC PAIN DRUG MARKET LICENSE & PRICING

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • Aptinyx Inc.
  • Assertio Holdings, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Axsome Therapeutics, Inc.
  • Bausch Health Companies Inc.
  • Baxter International Inc.
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • CARA THERAPEUTICS, INC.
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Grünenthal Group
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Scilex Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Trevena Inc.
  • Vertex Pharmaceuticals Incorporated

Methodology

Loading
LOADING...

Table Information